Roughly 1 in 8 US adults have taken GLP-1 drugs like Wegovy, poll shows [Reuters]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Reuters
The data also showed that 6% of those polled said they were currently using a GLP-1 drug, such as Novo Nordisk's diabetes drug Ozempic or weight-loss treatment Wegovy, or Eli Lilly's obesity drug Zepbound. Report this ad WHY IT'S IMPORTANT The poll highlights the growing popularity of the medicines, even as Eli Lilly and Novo Nordisk race to increase supply of the treatments, which have faced intermittent shortages over the past year. BY THE NUMBERS Awareness about the treatments has also risen, the poll showed, with about one-third of adults now saying they have heard “a lot” about these drugs, up from 19% in July last year. Still, affordability remains a challenge. Adults with annual household incomes of $90,000 or greater were more likely than those with lower household incomes to say they have heard “a lot” about these drugs, the poll showed. About 54% of those who have taken GLP-1 drugs found it challenging to afford them, even with insurance. WHAT'S NEXT The c
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk's Once-Weekly Insulin Flagged With Risk Of Low Blood Sugar Ahead Of FDA Review [Yahoo! Finance]Yahoo! Finance
- Top Research Reports for Novo Nordisk, QUALCOMM & Caterpillar [Yahoo! Finance]Yahoo! Finance
- Fire at Novo Nordisk office building under control [CNBC]CNBC
- Weight-Loss Upstart Viking Needs a Deal to Vie With Lilly and Novo [BNN Bloomberg (Canada)]BNN Bloomberg
- Weight-Loss Upstart Viking Needs a Deal to Vie With Lilly and Novo [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 5/3/24 - Beat
NVO
Sec Filings
- 5/17/24 - Form 6-K
- 5/17/24 - Form SD
- 5/15/24 - Form 6-K
- NVO's page on the SEC website